The Loncar Cancer Immunotherapy Index seeks to track the combined performance of a basket of companies that develop therapies to treat cancer by harnessing the body's own immune system. Immunotherapy is a transformational field within the biotechnology space that is expected to become a foundational treatment for cancer over the next ten years.  The index will provide a metric to follow its progress as researchers advance new technologies for the benefit of courageous patients who fight the disease.  It is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach.